Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Dow Jones Industrial Average
) is trading up 179 points (+1%) at 17,619 as of Tuesday, Jul 28, 2015, 1:36 p.m. ET. During this time, 215.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 332.7 million. The NYSE advances/declines ratio sits at 2,253 issues advancing vs. 787 declining with 142 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be
), which is sporting a 44-cent gain (+0.8%) bringing the stock to $57.43. This single gain is lifting the Dow Jones Industrial Average by 3.33 points or roughly accounting for 1.9% of the Dow's overall gain. Volume for Merck currently sits at 8.6 million shares traded vs. an average daily trading volume of 9.8 million shares.
Merck has a market cap of $162.2 billion and is part of the health care sector and drugs industry. Shares are up 0.3% year-to-date as of Monday's close. The stock's dividend yield sits at 3.1%.
Merck & Co., Inc. provides health care solutions worldwide.
TheStreet Ratings rates Merck as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Merck Ratings Report.